Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8

Immunological Reviews

Volumn 281, Issue 1, 2018, Pages 233-247

  Molgora, Martina ^a   Supino, Domenico ^a   Mantovani, Alberto ^a,b,c   Garlanda, Cecilia ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b HUMANITAS UNIVERSITY   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Infection; Inflammation; Inflammation associated cancer; Interleukin 1

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR 5; INTERLEUKIN 1 RECEPTOR 8; INTERLEUKIN 1 RECEPTOR 8ALPHA; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 37; UNCLASSIFIED DRUG; IL1R2 PROTEIN, HUMAN; SIGIRR PROTEIN, HUMAN;

ALLERGY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; AUTOIMMUNITY; BRAIN; BREAST TUMOR; CHRONIC LYMPHATIC LEUKEMIA; ENTERITIS; HUMAN; IMMUNITY; INFECTION; INFLAMMATION; INTESTINE CANCER; MALIGNANT NEOPLASM; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; THROMBOCYTE; ANIMAL; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOSURVEILLANCE; METABOLISM;

ANIMALS; HUMANS; IMMUNITY; IMMUNOLOGIC SURVEILLANCE; IMMUNOMODULATION; INFECTION; INFLAMMATION; KILLER CELLS, NATURAL; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE II;

EID: 85038005153     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12609     Document Type: Review

References (176)

1. Dinarello CA. Anti-inflammatory agents: present and future. Cell. 2010;140:935-950.
2. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003-1018.
3. Kang JY, Lee JO. Structural biology of the Toll-like receptor family. Annu Rev Biochem. 2011;80:917-941.
4. O’Neill LA. How Toll-like receptors signal: what we know and what we don’t know. Curr Opin Immunol. 2006;18:3-9.
5. O’Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev. 2008;226:10-18.
6. Dinarello CA. Immunological and inflammatory functions of the interleukin- 1 family. Annu Rev Immunol. 2009;27:519-550.
7. Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem. 2004;279:13677-13688.
8. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008;223:20-38.
9. Dinarello C, Arend W, Sims J, et al. IL-1 family nomenclature. Nat Immunol. 2010;11:973.
10. O’Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol. 2011;11:163-175.
11. Krelin Y, Voronov E, Dotan S, et al. Interleukin-1beta- driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007;67:1062-1071.
12. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010;10:103-110.
13. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720-3732.
14. Towne JE, Sims JE. IL-36 in psoriasis. Curr Opin Pharmacol. 2012;12:486-490.
15. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633-652.
16. Copeland NG, Silan CM, Kingsley DM, et al. Chromosomal location of murine and human IL-1 receptor genes. Genomics. 1991;9:44-50.
17. Morrison RN, Young ND, Nowak BF. Description of an Atlantic salmon (Salmo salar L.) type II interleukin-1 receptor cDNA and analysis of interleukin-1 receptor expression in amoebic gill disease-affected fish. Fish Shellfish Immunol. 2012;32:1185-1190.
18. Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science. 1993;261:472-475.
19. McMahan CJ, Slack JL, Mosley B, et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 1991;10:2821-2832.
20. Orlando S, Sironi M, Bianchi G, et al. Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem. 1997;272:31764-31769.
21. Lorenzen I, Lokau J, Dusterhoft S, et al. The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett. 2012;586:1093-1100.
22. Uchikawa S, Yoda M, Tohmonda T, et al. ADAM17 regulates IL-1 signaling by selectively releasing IL-1 receptor type 2 from the cell surface. Cytokine. 2015;71:238-245.
23. Martin P, Palmer G, Vigne S, et al. Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions. J Leuk Biol. 2013;94:791-802.
24. Giri JG, Wells J, Dower SK, et al. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol. 1994;153:5802-5809.
25. Colotta F, Orlando S, Fadlon EJ, et al. Chemoattractants induce rapid release of the interleukin 1 type II decoy receptor in human polymorphonuclear cells. J Exp Med. 1995;181:2181-2186.
26. Orlando S, Matteucci C, Fadlon EJ, et al. TNF-alpha, unlike other pro-and anti-inflammatory cytokines, induces rapid release of the IL-1 type II decoy receptor in human myelomonocytic cells. J Immunol. 1997;158:3861-3868.
27. Liu C, Hart RP, Liu XJ, et al. Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA. J Biol Chem. 1996;271:20965-20972.
28. Wang D, Zhang S, Li L, et al. Structural insights into the assembly and activation of IL-1beta with its receptors. Nat Immunol. 2010;11:905-911.
29. Re F, Sironi M, Muzio M, et al. Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface “receptor” with anti-interleukin- 1 function. J Exp Med. 1996;183:1841-1850.
30. Lang D, Knop J, Wesche H, et al. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol. 1998;161: 6871-6877.
31. Malinowsky D, Lundkvist J, Laye S, Bartfai T. Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett. 1998;429:299-302.
32. Laye S, Lundkvist J, Bartfai T. Human/mouse interleukin-1 receptor/ receptor accessory protein interactions in IL-1beta- induced NFkappaB activation. FEBS Lett. 1998;429:307-311.
33. Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA. 1995;92:1714-1718.
34. Smith DE, Hanna R, Della F, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity. 2003;18:87-96.
35. Kawaguchi Y, Nishimagi E, Tochimoto A, et al. Intracellular IL-1alpha- binding proteins contribute to biological functions of endogenous IL-1alpha in systemic sclerosis fibroblasts. Proc Natl Acad Sci USA. 2006;103:14501-14506.
36. Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MC. Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1alpha, controlling necrosis-induced sterile inflammation. Immunity. 2013;38:285-295.
37. Liu X, Hammel M, He Y, et al. Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci USA. 2013;110:14918-14923.
38. Colotta F, Saccani S, Giri JG, et al. Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes. J Immunol. 1996;156:2534-2541.
39. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to- macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177:7303-7311.
40. Mercer F, Kozhaya L, Unutmaz D. Expression and function of TNF and IL-1 receptors on human regulatory T cells. PLoS ONE. 2010;5:e8639.
41. Plitas G, Konopacki C, Wu K, et al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity. 2016;45: 1122-1134.
42. De Simone M, Arrigoni A, Rossetti G, et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity. 2016;45:1135-1147.
43. Fettelschoss A, Kistowska M, LeibundGut-Landmann S, et al. Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proc Natl Acad Sci USA. 2011;108:18055-18060.
44. Iwai H, Inaba M. Fetal thymus graft prevents age-related hearing loss and up regulation of the IL-1 receptor type II gene in CD4(+) T cells. J Neuroimmunol. 2012;250:1-8.
45. Tran DQ, Andersson J, Hardwick D, et al. Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/ CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood. 2009;113:5125-5133.
46. Drevets DA, Schawang JE, Mandava VK, Dillon MJ, Leenen PJ. Severe Listeria monocytogenes infection induces development of monocytes with distinct phenotypic and functional features. J Immunol. 2010;185:2432-2441.
47. Hofkens W, Schelbergen R, Storm G, van den Berg WB, van Lent PL. Liposomal targeting of prednisolone phosphate to synovial lining macrophages during experimental arthritis inhibits M1 activation but does not favor M2 differentiation. PLoS ONE. 2013;8:e54016.
48. Pou J, Martinez-Gonzalez J, Rebollo A, et al. Type II interleukin-1 receptor expression is reduced in monocytes/macrophages and atherosclerotic lesions. Biochim Biophys Acta. 2011;1811:556-563.
49. Pinteaux E, Parker LC, Rothwell NJ, Luheshi GN. Expression of interleukin- 1 receptors and their role in interleukin-1 actions in murine microglial cells. J Neurochem. 2002;83:754-763.
50. McNamee EN, Ryan KM, Kilroy D, Connor TJ. Noradrenaline induces IL-1ra and IL-1 type II receptor expression in primary glial cells and protects against IL-1beta- induced neurotoxicity. Eur J Pharmacol. 2010;626:219-228.
51. Trebec DP, Chandra D, Gramoun A, et al. Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases. J Cell Biochem. 2007;101:205-220.
52. Spriggs MK, Nevens PJ, Grabstein K, et al. Molecular characterization of the interleukin-1 receptor (IL-1R) on monocytes and polymorphonuclear cells. Cytokine. 1992;4:90-95.
53. Re F, Muzio M, De Rossi M, et al. The type II “receptor” as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med. 1994;179:739-743.
54. Colotta F, Re F, Muzio M, et al. Interleukin-13 induces expression and release of interleukin-1 decoy receptor in human polymorphonuclear cells. J Biol Chem. 1994;269:12403-12406.
55. Dickensheets HL, Donnelly RP. IFN-gamma and IL-10 inhibit induction of IL-1 receptor type I and type II gene expression by IL-4 and IL-13 in human monocytes. J Immunol. 1997;159:6226-6233.
56. Kalliolias GD, Gordon RA, Ivashkiv LB. Suppression of TNF-alpha and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27. J Immunol. 2010;185:7047-7056.
57. Daun JM, Ball RW, Burger HR, Cannon JG. Aspirin-induced increases in soluble IL-1 receptor type II concentrations in vitro and in vivo. J Leukoc Biol. 1999;65:863-866.
58. Penton-Rol G, Orlando S, Polentarutti N, et al. Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. J Immunol. 1999;162:2931-2938.
59. Docagne F, Campbell SJ, Bristow AF, et al. Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation. Eur J Neurosci. 2005;21:1205-1214.
60. Attur MG, Dave M, Cipolletta C, et al. Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem. 2000;275:40307-40315.
61. Giai C, Gonzalez CD, Sabbione F, et al. Staphylococcus aureus induces shedding of IL-1RII in monocytes and neutrophils. J Innate Immun. 2016;8:284-298.
62. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Immunol Today. 2000;21:447-455.
63. Rauschmayr T, Groves RW, Kupper TS. Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation. Proc Nat Acad Sci U S A. 1997;94:5814-5819.
64. Bessis N, Guery L, Mantovani A, et al. The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. Eur J Immunol. 2000;30:867-875.
65. Dawson J, Engelhardt P, Kastelic T, et al. Effects of soluble interleukin- 1 type II receptor on rabbit antigen-induced arthritis: clinical, biochemical and histological assessment. Rheumatology (Oxford). 1999;38:401-406.
66. Khoufache K, Bondza PK, Harir N, et al. Soluble human IL-1 receptor type 2 inhibits ectopic endometrial tissue implantation and growth: identification of a novel potential target for endometriosis treatment. Am J Pathol. 2012;181:1197-1205.
67. Simeoni E, Dudler J, Fleury S, et al. Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein improves cardiac allograft survival in rats. Eur J Cardiothorac Surg. 2007;31:222-228.
68. Chang H, Wang Y, Wu W, et al. Hydrodynamics-based delivery of an interleukin-1 receptor II fusion gene ameliorates rat autoimmune myocarditis by inhibiting IL-1 and Th17 cell polarization. Int J Mol Med. 2013;31:833-840.
69. Shimizu K, Nakajima A, Sudo K, et al. IL-1 receptor type 2 suppresses collagen-induced arthritis by inhibiting IL-1 signal on macrophages. J Immunol. 2015;194:3156-3168.
70. Martin P, Palmer G, Rodriguez E, et al. Deficiency in IL-1 receptor type 2 aggravates K/BxN serum transfer-induced arthritis in mice but has no impact on systemic inflammatory responses. J Immunol. 2017;198:2916-2926.
71. Lamacchia C, Palmer G, Bischoff L, et al. Distinct roles of hepatocyte- and myeloid cell-derived IL-1 receptor antagonist during endotoxemia and sterile inflammation in mice. J Immunol. 2010;185: 2516-2524.
72. Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci USA. 1996;93:11008-11013.
73. Kovach MA, Stringer KA, Bunting R, et al. Microarray analysis identifies IL-1 receptor type 2 as a novel candidate biomarker in patients with acute respiratory distress syndrome. Respir Res. 2015;16:29.
74. Chan KY, Leung FW, Lam HS, et al. Immunoregulatory protein profiles of necrotizing enterocolitis versus spontaneous intestinal perforation in preterm infants. PLoS ONE. 2012;7:e36977.
75. Muller B, Peri G, Doni A, et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol. 2002;72:643-649.
76. Dujmovic I, Mangano K, Pekmezovic T, et al. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol. 2009;207:101-106.
77. Arend WP, Malyak M, Smith MF Jr, et al. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol. 1994;153:4766-4774.
78. Jouvenne P, Vannier E, Dinarello CA, Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum. 1998;41:1083-1089.
79. Garlind A, Brauner A, Hojeberg B, Basun H, Schultzberg M. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer’s disease patients. Brain Res. 1999;826:112-116.
80. Meusch U, Klingner M, Baerwald C, Rossol M, Wagner U. Deficient spontaneous in vitro apoptosis and increased tmTNF reverse signaling-induced apoptosis of monocytes predict suboptimal therapeutic response of rheumatoid arthritis to TNF inhibition. Arthritis Res Ther. 2013;15:R219.
81. van der Torren CR, Verrijn Stuart AA, Lee D, et al. Serum cytokines as biomarkers in islet cell transplantation for type 1 diabetes. PLoS ONE. 2016;11:e0146649.
82. Debets R, Hegmans JP, Croughs P, et al. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol. 1997;158:2955-2963.
83. Ruckert F, Dawelbait G, Winter C, et al. Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis. PLoS ONE. 2010;5:e12243.
84. Ricote M, Garcia-Tunon I, Bethencourt FR, et al. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer. 2004;100:1388-1396.
85. Laios A, O’Toole SA, Flavin R, et al. An integrative model for recurrence in ovarian cancer. Mol Cancer. 2008;7:8.
86. Keita M, AinMelk Y, Pelmus M, Bessette P, Aris A. Endometrioid ovarian cancer and endometriotic cells exhibit the same alteration in the expression of interleukin-1 receptor II: to a link between endometriosis and endometrioid ovarian cancer. J Obstet Gynaecol Res. 2011;37:99-107.
87. Mora-Buch R, Dotti I, Planell N, et al. Epithelial IL-1R2 acts as a homeostatic regulator during remission of ulcerative colitis. Mucosal Immunol. 2015;9:950-959.
88. Kuznetsov NV, Zargari A, Gielen AW, et al. Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients. BMC Gastroenterol. 2014;14:79.
89. Thomassen E, Renshaw BR, Sims JE. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine. 1999;11:389-399.
90. Riva F, Polentarutti N, Tribbioli G, et al. The expression pattern of TIR8 is conserved among vertebrates. Vet Immunol Immunopathol. 2009;131:44-49.
91. Zhao J, Bulek K, Gulen MF, et al. Human colon tumors express a dominant-negative form of SIGIRR that promotes inflammation and colitis-associated colon cancer in mice. Gastroenterology. 2015;149:1860-1871, e1868.
92. Polentarutti N, Rol GP, Muzio M, et al. Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR. Eur Cytokine Netw. 2003;14:211-218.
93. Kadota C, Ishihara S, Aziz MM, et al. Down-regulation of single immunoglobulin interleukin-1R- related molecule (SIGIRR)/TIR8 expression in intestinal epithelial cells during inflammation. Clin Exp Immunol. 2010;162:348-361.
94. Khan MA, Steiner TS, Sham HP, et al. The single IgG IL-1- related receptor controls TLR responses in differentiated human intestinal epithelial cells. J Immunol. 2010;184:2305-2313.
95. Batliwalla FM, Li W, Ritchlin CT, et al. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med. 2005;11:21-29.
96. Ragnarsdottir B, Samuelsson M, Gustafsson MC, et al. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis. 2007;196:475-484.
97. Nanthakumar N, Meng D, Goldstein AM, et al. The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: an immature innate immune response. PLoS ONE. 2011;6:e17776.
98. Veliz Rodriguez T, Moalli F, Polentarutti N, et al. Role of Toll interleukin- 1 receptor (IL-1R) 8, a negative regulator of IL-1R/ Toll-like receptor signaling, in resistance to acute Pseudomonas aeruginosa lung infection. Infect Immun. 2012;80:100-109.
99. Gopal R, Birdsell D, Monroy FP. Regulation of toll-like receptors in intestinal epithelial cells by stress and Toxoplasma gondii infection. Parasite Immunol. 2008;30:563-576.
100. Leemans JC, Butter LM, Teske GJ, et al. The toll interleukin-1 receptor (IL-1R) 8/single Ig domain IL-1R- related molecule modulates the renal response to bacterial infection. Infect Immun. 2012;80:3812-3820.
101. Li D, Zhang X, Chen B. SIGIRR participates in negative regulation of LPS response and tolerance in human bladder epithelial cells. BMC Immunol. 2015;16:73.
102. Anselmo A, Riva F, Gentile S, et al. Expression and function of IL-1R8 (TIR8/SIGIRR): a regulatory member of the IL-1 receptor family in platelets. Cardiovasc Res. 2016;111:373-384.
103. Vilia MG, Fonte E, Veliz Rodriguez T, et al. The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/ SIGIRR) is downregulated in chronic lymphocytic leukemia. Leuk Lymphoma. 2017;58:2419-2425.
104. Campesato LF, Silva APM, Cordeiro L, et al. High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity. Oncotarget. 2017;8:49470-49483.
105. Ueno-Shuto K, Kato K, Tasaki Y, et al. Lipopolysaccharide decreases single immunoglobulin interleukin-1 receptor-related molecule (SIGIRR) expression by suppressing specificity protein 1 (Sp1) via the Toll-like receptor 4 (TLR4)-p38 pathway in monocytes and neutrophils. J Biol Chem. 2014;289:18097-18109.
106. Adib-Conquy M, Adrie C, Fitting C, et al. Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients. Crit Care Med. 2006;34:2377-2385.
107. Jiang X, McClellan SA, Barrett RP, Zhang Y, Hazlett LD. Vasoactive intestinal peptide downregulates proinflammatory TLRs while upregulating anti-inflammatory TLRs in the infected cornea. J Immunol. 2012;189:269-278.
108. Villena J, Suzuki R, Fujie H, et al. Immunobiotic Lactobacillus jensenii modulates the Toll-like receptor 4-induced inflammatory response via negative regulation in porcine antigen-presenting cells. Clin Vaccine Immunol. 2012;19:1038-1053.
109. Davies JM, MacSharry J, Shanahan F. Differential regulation of Toll-like receptor signalling in spleen and Peyer’s patch dendritic cells. Immunology. 2010;131:438-448.
110. Bulek K, Swaidani S, Qin J, et al. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol. 2009;182:2601-2609.
111. Costello DA, Carney DG, Lynch MA. alpha-TLR2 antibody attenuates the Abeta-mediated inflammatory response in microglia through enhanced expression of SIGIRR. Brain Behav Immun. 2015;46:70-79.
112. Vilia MG, Tocchetti M, Fonte E, Sana I, Muzio M. Characterization of a long isoform of IL-1R8 (TIR8/SIGIRR). Eur Cytokine Netw. 2017;28:63-69.
113. Wald D, Qin J, Zhao Z, et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol. 2003;4:920-927.
114. Garlanda C, Riva F, Polentarutti N, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA. 2004;101:3522-3526.
115. Qin J, Qian Y, Yao J, Grace C, Li X. SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem. 2005;280:25233-25241.
116. Lech M, Garlanda C, Mantovani A, et al. Different roles of TiR8/Sigirr on toll-like receptor signaling in intrarenal antigen-presenting cells and tubular epithelial cells. Kidney Int. 2007;72:182-192.
117. Tomasoni R, Morini R, Lopez-Atalaya JP, et al. Lack of IL-1R8 in neurons causes hyperactivation of IL-1 receptor pathway and induces MECP2-dependent synaptic defects. Elife. 2017;6:e21735.
118. Molgora M, Bonavita E, Ponzetta A, et al. IL-1R8 is a checkpoint in NK cells regulating anti-tumor and anti-viral activity. Nature. 2017;551:110-114.
119. Li X, Qin J. Modulation of Toll-interleukin 1 receptor mediated signaling. J Mol Med (Berl). 2005;83:258-266.
120. Gong J, Wei T, Stark RW, et al. Inhibition of Toll-like receptors TLR4 and 7 signaling pathways by SIGIRR: a computational approach. J Struct Biol. 2010;169:323-330.
121. Guven-Maiorov E, Keskin O, Gursoy A, Nussinov R. a structural view of negative regulation of the toll-like receptor-mediated inflammatory pathway. Biophys J. 2015;109:1214-1226.
122. Kobayashi K, Hernandez LD, Galan JE, et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 2002;110:191-202.
123. Garlanda C, Anders HJ, Mantovani A. TIR8/SIGIRR: an IL-1R/ TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol. 2009;30:439-446.
124. Drexler SK, Kong P, Inglis J, et al. SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis. Arthritis Rheum. 2010;62:2249-2261.
125. Gulen MF, Kang Z, Bulek K, et al. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity. 2010;32: 54-66.
126. Xiao H, Yin W, Khan MA, et al. Loss of single immunoglobulin interlukin- 1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. Gastroenterology. 2010;139:574-585.
127. Patterson NJ, Werling D. To con protection: TIR-domain containing proteins (Tcp) and innate immune evasion. Vet Immunol Immunopathol. 2013;155:147-154.
128. Newman RM, Salunkhe P, Godzik A, Reed JC. Identification and characterization of a novel bacterial virulence factor that shares homology with mammalian Toll/interleukin-1 receptor family proteins. Infect Immun. 2006;74:594-601.
129. Low LY, Mukasa T, Reed JC, Pascual J. Characterization of a TIR-like protein from Paracoccus denitrificans. Biochem Biophys Res Comm 2007;356:481-486.
130. Imbert PR, Louche A, Luizet JB, et al. A Pseudomonas aeruginosa TIR effector mediates immune evasion by targeting UBAP1 and TLR adaptors. EMBO J. 2017;36:1869-1887.
131. Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11:1014-1022.
132. Nold-Petry CA, Lo CY, Rudloff I, et al. IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol. 2015;16:354-365.
133. Li S, Neff CP, Barber K, et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci USA. 2015;112:2497-2502.
134. Moretti S, Bozza S, Oikonomou V, et al. IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog. 2014;10:e1004462.
135. Lunding L, Webering S, Vock C, et al. IL-37 requires IL-18Ralpha and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice. Allergy. 2015;70:366-373.
136. Ballak DB, van Diepen JA, Moschen AR, et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 2014;5:4711.
137. Cavalli G, Justice JN, Boyle KE, et al. Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. Proc Natl Acad Sci USA. 2017;114:2313-2318.
138. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46-56.
139. Garlanda C, Di Liberto D, Vecchi A, et al. Damping excessive inflammation and tissue damage in Mycobacterium tuberculosis infection by Toll IL-1 receptor 8/single Ig IL-1- related receptor, a negative regulator of IL-1/ TLR signaling. J Immunol. 2007;179: 3119-3125.
140. Huang X, Hazlett LD, Du W, Barrett RP. SIGIRR promotes resistance against Pseudomonas aeruginosa keratitis by down-regulating type-1 immunity and IL-1R1 and TLR4 signaling. J Immunol. 2006;177:548-556.
141. Bozza S, Zelante T, Moretti S, et al. Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection. J Immunol. 2008;180:4022-4031.
142. Horne DJ, Randhawa AK, Chau TT, et al. Common polymorphisms in the PKP3-SIGIRR- TMEM16J gene region are associated with susceptibility to tuberculosis. J Infect Dis. 2012;205:586-594.
143. Blok DC, van Lieshout MH, Hoogendijk AJ, et al. Single immunoglobulin interleukin-1 receptor-related molecule impairs host defense during pneumonia and sepsis caused by Streptococcus pneumoniae. J Innate Immun. 2014;6:542-552.
144. Sham HP, Yu EY, Gulen MF, et al. SIGIRR, a negative regulator of TLR/IL-1R signalling promotes Microbiota dependent resistance to colonization by enteric bacterial pathogens. PLoS Pathog. 2013;9:e1003539.
145. Drexler SK, Foxwell BM. The role of toll-like receptors in chronic inflammation. Int J Biochem Cell Biol. 2010;42:506-518.
146. Russell SE, Stefanska AM, Kubica M, et al. Toll IL-1R8/ single Ig IL-1- related receptor regulates psoriasiform inflammation through direct inhibition of innate IL-17A expression by gammadelta T cells. J Immunol. 2013;191:3337-3346.
147. Lech M, Kulkarni OP, Pfeiffer S, et al. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med. 2008;205:1879-1888.
148. Lech M, Skuginna V, Kulkarni OP, et al. Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus nephritis. J Pathol. 2010;220:596-607.
149. Wang DY, Su C, Chen GM, et al. The decreased frequency of SIGIRR-positive CD4+ T cells in peripheral blood of patients with SLE and its correlation with disease activity. Mol Biol Rep. 2015;42:423-430.
150. Sanchez E, Garcia-Bermudez M, Jimenez-Alonso J, et al. Association study of IRAK-M and SIGIRR genes with SLE in a large European-descent population. Lupus. 2012;21:1166-1171.
151. Zhu Y, Wang DG, Yang XK, et al. Emerging role of SIGIRR rs7396562(T/G) polymorphism in systemic lupus erythematosus in a Chinese population. Inflammation. 2014;37:1847-1851.
152. Nakashima K, Hirota T, Obara K, et al. An association study of asthma and related phenotypes with polymorphisms in negative regulator molecules of the TLR signaling pathway. J Hum Genet. 2006;51:284-291.
153. Lech M, Avila-Ferrufino A, Allam R, et al. Resident dendritic cells prevent postischemic acute renal failure by help of single Ig IL-1 receptor-related protein. J Immunol. 2009;183:4109-4118.
154. Noris M, Cassis P, Azzollini N, et al. The Toll-IL- 1R member Tir8/ SIGIRR negatively regulates adaptive immunity against kidney grafts. J Immunol. 2009;183:4249-4260.
155. Costelloe C, Watson M, Murphy A, et al. IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8. J Neurochem. 2008;105: 1960-1969.
156. Andre R, Lerouet D, Kimber I, Pinteaux E, Rothwell NJ. Regulation of expression of the novel IL-1 receptor family members in the mouse brain. J Neurochem. 2005;95:324-330.
157. Watson MB, Costello DA, Carney DG, McQuillan K, Lynch MA. SIGIRR modulates the inflammatory response in the brain. Brain Behav Immun. 2010;24:985-995.
158. Costello DA, Watson MB, Cowley TR, et al. Interleukin-1alpha and HMGB1 mediate hippocampal dysfunction in SIGIRR-deficient mice. J Neurosci. 2011;31:3871-3879.
159. Na ES, Nelson ED, Kavalali ET, Monteggia LM. The impact of MeCP2 loss-or gain-of- function on synaptic plasticity. Neuropsychopharmacology. 2013;38:212-219.
160. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355:581-592.
161. Xiao H, Gulen MF, Qin J, et al. The Toll-interleukin- 1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity. 2007;26:461-475.
162. Garlanda C, Riva F, Veliz T, et al. Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res. 2007;67:6017-6021.
163. Yamada Y, Hata K, Hirose Y, et al. Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc(Min/+) mice. Cancer Res. 2002;62:6367-6370.
164. Muzio M, Bertilaccio MT, Simonetti G, Frenquelli M, Caligaris-Cappio F. The role of toll-like receptors in chronic B-cell malignancies. Leuk Lymphoma. 2009;50:1573-1580.
165. Muzio M, Scielzo C, Bertilaccio MT, et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 2009;144:507-516.
166. Bertilaccio MT, Simonetti G, Dagklis A, et al. Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. Blood. 2011;118:660-669.
167. Arvaniti E, Ntoufa S, Papakonstantinou N, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica. 2011;96:1644-1652.
168. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA. 2002;99:6955-6960.
169. Brown GT, Narayanan P, Li W, Silverstein RL, McIntyre TM. Lipopolysaccharide stimulates platelets through an IL-1beta autocrine loop. J Immunol. 2013;191:5196-5203.
170. Beaulieu LM, Freedman JE. The role of inflammation in regulating platelet production and function: Toll-like receptors in platelets and megakaryocytes. Thromb Res 2010;125:205-209.
171. Levi M, Lowenberg EC. Thrombocytopenia in critically ill patients. Semin Thromb Hemost 2008;34:417-424.
172. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-444.
173. Chaix J, Tessmer MS, Hoebe K, et al. Cutting edge: priming of NK cells by IL-18. J Immunol. 2008;181:1627-1631.
174. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17:1025-1036.
175. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16:7-19.
176. Stojanovic A, Cerwenka A. Natural killer cells and solid tumors. J Innate Immun. 2011;3:355-364.